Identification of serum proteins AHSG, FGA and APOA-I as diagnostic biomarkers for gastric cancer

Abstract

BackgroundThe development of clinically accessible biomarkers is critical for the early diagnosis of gastric cancer (GC) in patients. High-throughput proteomics techniques could not only effectively generate a serum peptide profile but also provide a new approach to identify potentially diagnostic and prognostic biomarkers for cancer patients.MethodsIn this study, we aim to identify potentially discriminating serum biomarkers for GC. In the discovery cohort, we screened potential biomarkers using magnetic-bead-based purification and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in 64 samples from 32 GC patients that were taken both pre- and post-operatively and 30 healthy volunteers that served as controls. In the validation cohort, the expression patterns and diagnostic values of serum FGA, AHSG and APOA-I were further confirmed by ELISA in 42 paired GC patients (pre- and post-operative samples from 16 patients with pathologic stage I/II and 26 with stage III/IV), 30 colorectal cancer patients, 30 hepatocellular carcinoma patients, and 28 healthy volunteers.ResultsClinProTools software was used and annotated 107 peptides, 12 of which were differentially expressed among three groups (P < 0.0001, fold > 1.5). These 12 peptide peaks were further identified as FGA, AHSG, APOA-I, HBB, TXNRD1, GSPT2 and CAKP5. ELISA data suggested that the serum levels of FGA, AHSG and APOA-I in GC patients were significantly different compared with healthy controls and had favorable diagnostic values for GC patients. Moreover, we found that the serum levels of these three proteins were associated with TNM stages and could reflect tumor burden.ConclusionOur findings suggested that FGA, AHSG and APOA-I might be potential serum biomarkers for GC diagnosis.Electronic supplementary materialThe online version of this article (10.1186/s12014-018-9194-0) contains supplementary material, which is available to authorized users.

Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma

“…Little is known about HIST1H2BK in previous cancer studies. For certain markers identified here, their potential for non-invasive cancer diagnosis has been reported previously, such as serum TIMP1 and FGA proteins used for the diagnosis of PDAC and gastric cancer, respectively 36–38. Collectively, these results suggested that plasma EVs contain a considerable number of exLRs that are potential biomarkers for PDAC detection.…”

Proteomics profiling of plasma exosomes in epithelial ovarian cancer: A potential role in the coagulation cascade, diagnosis and prognosis

“…For instance, Davalieva et al reported the non-invasive biomarkers in urine with higher specificity than prostate-specific antigen (PSA) in patients with prostate cancer; a number of genes, including FGG and FGA were observed to be present with different abundances, which could be potential biomarker candidates (41). In another study, the serum levels of the proteins, alpha 2-HS glycoprotein (AHSG), FGA and apolipoprotein A1 (APOA-I), were identified as diagnostic biomarkers for gastric cancer (GC); ELISA data suggested that the serum levels of FGA, AHSG and APOA-I in patients with GC differed significantly as compared to the healthy volunteers; moreover, the serum levels of these three proteins were associated with TNM stages and could reflect tumor burden (42). The FGG gene mediates the formation of the fibrinogen γ chain, a subunit of the fibrinogen protein.…”

Downregulation of Fat Mass and Obesity Associated (FTO) Promotes the Progression of Intrahepatic Cholangiocarcinoma

“…SCML4 was reported to be downregulated in breast cancer stem cells (41). However, APOA2, NTRK2 , and FGA are oncogenes in PDAC, glioblastoma, and gastric cancer (42–45). Thus, FTO may inhibit ICC progression by reducing oncogene expression ( TEAD2 and CMTM4 ) and inducing tumor suppressor expression ( HAO2, NR5A2, CCL19, TCF21, NTRK2 , and SCML4 ).…”